900 Children Join UAE's Sinopharm Vaccine Study

  • Publish date: Monday، 02 August 2021
900 Children Join UAE's Sinopharm Vaccine Study

The Abu Dhabi Department of Health, the regulatory body for the healthcare sector in the emirate, announced that the target number for the trial study for the immune response to the “Sinopharmvaccine for children aged 3 to 17 years has been reached.

The study was approved by the department under the supervision of the Ministry of Health and Community Protection, after proving the effectiveness of the vaccine in reducing the incidence and severity of symptoms among the target groups.

The department explained that the study witnessed a large turnout from volunteer children and their families, as each child participated in this study after the full approval of the guardian, noting that "they will be subjected to close monitoring and follow-up."

"Parents and children have been provided with full details about participation and will receive the necessary support during every step of it," she added.

The Department of Health - Abu Dhabi praised the great role played by the Abu Dhabi Health Services Company "SEHA" in completing the supplementary study and its efforts to move forward with the application of medical procedures and protocols in place to achieve the study's objectives.

The UAE is the first country in the Middle East and North Africa to conduct a study of the effectiveness of the vaccine for this age group, while vaccine-manufacturing countries such as China, the United States of America, Britain and India began conducting clinical trials for them during the past few months.

The trial study saw the participation of 900 children of all nationalities. It is expected that the preliminary results of the study will be announced as soon as they become available, which will help in the planning and preparation process for returning to school and the safety of students.